Phase 2a Study to Assess CIVI 007 in Patients on a Background of Statin Therapy
Status:
Completed
Trial end date:
2020-11-17
Target enrollment:
Participant gender:
Summary
Evaluation of the clinical profile (lipid efficacy, safety and PK) across a number of doses
of CIVI 007, a PCSK9 inhibitor. Patients to be evaluated will be on a stable background of
statin therapy with or without ezetimibe.